2025-07-16
13:39 |
|
8 p, 1.8 MB |
CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells
/
Mensurado, Sofía (Universidade de Lisboa) ;
Condeço, C. (Universidade de Lisboa) ;
Sánchez Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Shirley, S. (Universidade de Lisboa) ;
Coelho, R.M.L. (Universidade de Lisboa) ;
Tirado, Nestor (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blanco-Domínguez, Rafael (Universidade de Lisboa) ;
Barros, L. (Universidade de Lisboa) ;
Galvão, B. (Universidade de Lisboa) ;
Custódio, N. (Universidade de Lisboa) ;
Gomes da Silva, Maria (Instituto Português de Oncologia Francisco Gentil) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Silva-Santos, Bruno (Universidade de Lisboa) ;
Universitat Autònoma de Barcelona
Relapsed or refractory acute myeloid leukemia (AML) remains a major therapeutic challenge. We have recently developed a Vδ1 γδ T cell-based product for adoptive immunotherapy, named Delta One T (DOT) cells, and demonstrated their cytolytic capacity to eliminate AML cell lines and primary blasts in vitro and in vivo. [...]
2024 -  10.1182/blood.2023022992
Blood, Vol. 143 Núm. 15 (november 2024) , p. 1488-1495
|
|
2025-07-16
13:38 |
|
15 p, 3.9 MB |
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands
/
Díaz-Tejedor, A. (Instituto de Investigación Biomédica de Salamanca) ;
Rodríguez-Ubreva, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ciudad, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lorenzo-Mohamed, M. (Instituto de Investigación Biomédica de Salamanca) ;
González-Rodríguez, M. (Instituto de Investigación Biomédica de Salamanca) ;
Castellanos, B. (Instituto de Investigación Biomédica de Salamanca) ;
Sotolongo-Ravelo, J. (Instituto de Investigación Biomédica de Salamanca) ;
San-Segundo, L. (Instituto de Investigación Biomédica de Salamanca) ;
Corchete, L.A. (Centro de Investigación Biomédica en Red de Cáncer) ;
González-Méndez, L. (Instituto de Investigación Biomédica de Salamanca) ;
Martín-Sánchez, M. (Instituto de Investigación Biomédica de Salamanca) ;
Mateos, M. V. (Universidad de Salamanca. Departamento de Medicina) ;
Ocio, Enrique M. (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Garayoa, M. (Instituto de Investigación Biomédica de Salamanca) ;
Paíno, T. (Universidad de Salamanca) ;
Universitat Autònoma de Barcelona
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. [...]
2024 - 10.3390/ijms25094718
International journal of molecular sciences, Vol. 25 Núm. 9 (may 2024) , p. 4718
|
|
2025-07-16
04:34 |
|
7 p, 618.4 KB |
Beyond myeloid neoplasms germline guidelines : Validation of the thresholds criteria in the search of germline predisposition variants
/
Mestre, Julia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Chaparro, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sole, F (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. [...]
2024 - 10.1002/jha2.1012
EJHaem, Vol. 5 (october 2024) , p. 1021-1027
|
|
2025-07-16
04:34 |
|
11 p, 2.6 MB |
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
/
Oñate, Guadalupe (Institut d'Investigació Biomèdica Sant Pau) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Arnan, Montserrat (Institut d'Investigació Biomèdica de Bellvitge) ;
Pomares, Helena (Institut d'Investigació Biomèdica de Bellvitge) ;
Alonso, Ester (Institut d'Investigació Biomèdica de Bellvitge) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Vives Polo, Susana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
Salamero, Olga (Vall d'Hebron Institut d'Oncologia) ;
Cervera, Marta (Hospital Universitari Joan XXIII de Tarragona) ;
Garcia, Antoni (Hospital Universitari Arnau de Vilanova) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Garcia-Avila, Sara (Hospital del Mar (Barcelona, Catalunya)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Ortin, Xavier (Hospital de Tortosa Verge de la Cinta) ;
Iranzo, Eva (Institut d'Investigació Biomèdica Sant Pau) ;
Guijarro, Francesca (Hospital Clínic i Provincial de Barcelona) ;
Pratcorona, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Nomdedéu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau)
Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will perform poorly, and in whom alternative approaches deserve investigation. [...]
2025 - 10.1038/s41408-024-01205-5
Blood Cancer Journal, Vol. 15 Num. 4 (January 2025)
|
|
2025-06-24
06:35 |
|
17 p, 1.6 MB |
Multikinase Treatment of Glioblastoma : Evaluating the Rationale for Regorafenib
/
Muñoz-Mármol, Ana Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Meléndez, Bárbara (Complejo Hospitalario de Toledo) ;
Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Arpí-Llucia, Oriol (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gut, Marta (Universitat de Barcelona) ;
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Esteve-Codina, Anna (Universitat de Barcelona) ;
Parra, Genis (Universitat de Barcelona) ;
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aldecoa, Iban (Universitat de Barcelona) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pineda, Estela (Hospital Clínic i Provincial de Barcelona) ;
Alameda, Francesc (Institut Hospital del Mar d'Investigacions Mèdiques) ;
de la Iglesia, Nuria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Estival, Anna (Hospital Universitario Insular de Gran Canaria) ;
Balañá, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
For a targeted drug to be effective, the target must be present. To determine if this condition was met for regorafenib in glioblastoma, we analyzed 46 genes encoding protein kinases (PKs) inhibited by regorafenib in preclinical studies. [...]
2025 - 10.3390/cancers17030375
Cancers, Vol. 17 (january 2025)
|
|
2025-05-14
14:00 |
|
12 p, 3.0 MB |
Insights into the human cDNA : A descriptive study using library screening in yeast
/
Alaswad, Z. (University of Science and Technology. Zewail City of Science and Technology) ;
Attallah, N.E. (University of Science and Technology. Zewail City of Science and Technology) ;
Aboalazm, B. (University of Science and Technology. Zewail City of Science and Technology) ;
Elmeslhy, E.S. (University of Science and Technology. Zewail City of Science and Technology) ;
Mekawy, A.S. (University of Science and Technology. Zewail City of Science and Technology) ;
Afify, F.A. (University of Science and Technology. Zewail City of Science and Technology) ;
Mahrous, H.K. (University of Science and Technology. Zewail City of Science and Technology) ;
Abdalla, A. (University of Science and Technology. Zewail City of Science and Technology) ;
Rahmoon, M.A. (German University in Cairo) ;
Mohamed, A.A. (University of Science and Technology. Zewail City of Science and Technology) ;
Shata, A.H. (University of Science and Technology. Zewail City of Science and Technology) ;
Mansour, R.H. (Center for Genomics. Helmy Institute for Medical Sciences. Zewail City of Science and Technology) ;
Aboul-ela, F. (Center for X-Ray Determination of the Structure of Matter. Zewail City of Science and Technology) ;
Elhadidy, M. (University of Science and Technology. Zewail City of Science and Technology) ;
Javierre, B. M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
El-Khamisy, S.F. (The Institute of Cancer Therapeutics. University of Bradford) ;
Elserafy, M. (University of Science and Technology. Zewail City of Science and Technology) ;
Universitat Autònoma de Barcelona
The utilization of human cDNA libraries in yeast genetic screens is an approach that has been used to identify novel gene functions and/or genetic and physical interaction partners through forward genetics using yeast two-hybrid (Y2H) and classical cDNA library screens. [...]
2024 - 10.1016/j.jgeb.2024.100427
Journal of Genetic Engineering and Biotechnology, Vol. 22 Núm. 4 (december 2024) , p. 100427
|
|
2025-05-14
14:00 |
|
3 p, 1020.2 KB |
The SIRT7-nucleolus connection in cancer : ARF enters the fray
/
Tarighi, S. (Max-Planck-Institute for Heart and Lung Research) ;
Kumari, P. (Max-Planck-Institute for Heart and Lung Research) ;
Vaquero, Alejandro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Braun, T. (The German Center for Lung Research (DZL). The Cardio-Pulmonary Institute (CPI)) ;
Ianni, Alessandro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
The nucleolar enzyme sirtuin 7 (SIRT7) promotes cancer progression in certain malignancies, likely in part by controlling ribosome biosynthesis. Recently, we discovered that SIRT7 destabilizes the cyclin dependent kinase inhibitor 2A (CDKN2A, known as ARF) within the nucleolus, aiding cancer progression. [...]
2024 - 10.1080/23723556.2024.2381287
Molecular & cellular oncology, Vol. 11 Núm. 1 (2024) , p. 2381287
|
|
2025-05-14
13:59 |
|
2025-05-14
13:59 |
|
13 p, 1.9 MB |
Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis
/
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pomares, Helena (Institut d'Investigació Biomèdica de Bellvitge) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Germing, Ulrich (Heinrich-Heine Universitätsklinikum) ;
Arnan, Montserrat (Institut d'Investigació Biomèdica de Bellvitge) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Palomo Sanchís, Laura (Hospital Universitari Vall d'Hebron) ;
Orna, Elisa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Della Porta, Matteo (IRCCS Humanitas (Rozzano, Itàlia)) ;
Schulz, Felicitas (Heinrich-Heine Universitätsklinikum) ;
Díaz-Beya, Marina (Hospital Clínic i Provincial de Barcelona) ;
Esteban, Ada (Hospital de San Pedro (Logroño, Espanya)) ;
Molero, Antonieta (Hospital Universitari Vall d'Hebron) ;
Lanino, Luca (IRCCS Humanitas (Rozzano, Itàlia)) ;
Avendaño, Alejandro (Hospital Universitario de Salamanca) ;
Hernández, Francisca (Hospital Universitario Virgen de las Nieves (Granada)) ;
Roldan, Verónica (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Ubezio, Marta (IRCCS Humanitas (Rozzano, Itàlia)) ;
Pineda, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Introduction: Chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) with ring sideroblasts (RS) or SF3B1 mutation (MDS-RS/SF3B1) differ in many clinical features, but share others, such as anemia. [...]
2024 - 10.3389/fonc.2024.1385987
Frontiers in Oncology, Vol. 14 (2024) , p. 1385987
|
|
2025-05-14
13:59 |
|
|
|
visitante ::
identificación
Estadísticas de uso
Los más consultados
